Your session is about to expire
← Back to Search
Thrombolysis vs FlowTriever System for Pulmonary Embolism (PEERLESS Trial)
PEERLESS Trial Summary
This trial is comparing a new device to a standard treatment for pulmonary embolism, in patients who can't have the standard treatment.
PEERLESS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPEERLESS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PEERLESS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I show signs of a severe pulmonary embolism.I am 18 years old or older.You have been diagnosed with heparin-induced thrombocytopenia (HIT).The doctor thinks you may not live for more than 30 days.The doctor thinks that it's not suitable to use a catheter for treatment based on the imaging or other evidence.I cannot use certain blood thinners like heparin.I have or had chronic lung blood clot issues as per 2019 guidelines.My initial symptoms included severe instability in my blood pressure or heart rate.My treatment is set to start within 72 hours after my PE diagnosis or hospital transfer.I cannot or do not want to follow the required visit schedule.My symptoms started within 14 days after my PE was confirmed.Your blood pressure in a specific part of your heart is too high before the study device is put in.I received clot-dissolving treatment or a clot removal procedure for my PE within the last 48 hours.You are allergic to X-ray contrast dye and the doctor doesn't think pre-treatment will help.You have a problem with the right side of your heart shown on an echocardiogram or CT scan.My heart has irregular beats that haven't improved with treatment.You have evidence of a blood clot in the main or lobar pulmonary artery from a specific type of test.You have a blood clot in your heart that was found during the initial screening.My heart and blood circulation are stable.I have had heart or lung issues, including high heart rate or low blood pressure at diagnosis.
- Group 1: Randomized Controlled Trial Cohort - FlowTriever Arm
- Group 2: Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm
- Group 3: Non-Randomized Absolute Contraindication to Thrombolytics Cohort
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are receiving treatment through this trial?
"Affirmative. According to clinicaltrials.gov, this trial is still in search of participants since it was first posted on February 14th 2022 and last updated November 9th later that year. The study requires the enrolment of 550 patients from 58 separate medical sites."
Is there capacity for additional participants in this research endeavor?
"The latest information from clinicaltrials.gov confirms that recruitment for this medical trial is ongoing. It was posted in mid-February 2022 and the data was recently updated on November 9th of the same year."
In what areas can participants access this research project?
"At this time, 58 medical centres are welcoming participants for enrolment. These sites span from Wilmington to Elk Grove Village and West Columbia as well as dozens of other places inbetween. To reduce the burden of travelling, we advise selecting a facility close by when signing up."
Share this study with friends
Copy Link
Messenger